Washington [US]: Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), have reported that an experimental therapeutic cancer vaccine induced two distinct and advantageous immune system responses that resulted in significant tumour regression in mice.
The delivery of the vaccine intravenously (IV) increased the number of cytotoxic T cells capable of penetrating and destroying tumour cells and activated the innate immune system by producing type I interferon, according to the researchers.
